Table 2 Cox proportional hazards model of factors that predict overall survival in men with CRPC receiving docetaxel (n=55)
From: Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer
Univariable | Multivariable | ||||
|---|---|---|---|---|---|
Variable | n | HR (95% CI) | P -value | HR (95% CI) | P -value |
Baseline MIC-1 level >median vs ⩽median | 55 | 2.819 (1.517–5.240) | 0.001 | 2.728 (1.178–6.32) | 0.02 |
Hemoglobina, g l−1 | 55 | 0.013 (0.001–0.141) | <0.001 | 0.025 (0.02–0.308) | 0.004 |
Serum alkaline phosphatasea, IU l−1 | 45 | 1.688 (1.246–2.286) | 0.001 | 1.34 (0.928–1.936) | 0.1 |
Progressive disease on chemotherapy (PD vs SD+PR) | 55 | 3.462 (1.327–9.037) | 0.011 | 2.288 (0.51–10.36) | 0.3 |
Baseline serum PSAa, ng ml−1 | 55 | 1.356 (1.093–1.681) | 0.006 | 1.095 (0.786–1.525) | 0.6 |
Fall in PSA over 12 weeks <30% vs ⩾30% | 55 | 2.591 (1.288–5.209) | 0.008 | 1.271 (0.465–3.474) | 0.6 |
Gleason score | 44 | 1.222 (0.887–1.683) | 0.2 | — | — |
Metastatic site | 55 | ||||
None | 0.47 (0.14–2.50) | 0.5 | |||
Bone only | 1.0 | ||||
Visceral/soft tissue | 2.64 (1.15–6.10) | 0.02 | — | — | |
Bone and visceral | 2.82 (1.36–5.83) | 0.05 | |||
Change in MIC1/IL-4/IL-6 levels after cycle 1 chemotherapy | 55 | 1.019 (0.882–1.177) | 0.8 | — | — |
